TERF2IP

Across TCGA pan-cancer cohorts, TERF2IP Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TERF2IP data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TERF2IP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TERF2IP expression acts as an unfavorable survival marker.

STAD, BRCA, and PRAD are the cancer types where TERF2IP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.001	0.667	<.001	36	view →
BRCA	OS	Median	All	0.514	0.963	.006	12	view →
PRAD	DFS	Median	All	0.111	0.886	<.001	8	view →
SKCM	DFS	Median	II,III,IV	0.198	0.682	.027	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TERF2IP–STAD (OS)

Open the STAD breakdown →